imm2520
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 23, 2023 (NCT05780307)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05780307 | Phase 1 | Mar 23, 2023 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd, Shandong University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd | For profit | 1 | 1 | 1 | 2023 |
| Shandong University | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1